Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Public ClinicalTrials.gov record NCT00814086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Study identification
- NCT ID
- NCT00814086
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Enrollment
- 23 participants
Conditions and interventions
Conditions
- Chemotherapeutic Agent Toxicity
- Endometrial Adenocarcinoma
- Fallopian Tube Carcinoma
- Gastrointestinal Complication
- Malignant Ovarian Mixed Epithelial Tumor
- Neurotoxicity Syndrome
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Primary Peritoneal Carcinoma
- Stage II Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- Undifferentiated Ovarian Carcinoma
Interventions
- Cisplatin Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Not listed
- Last update posted
- Dec 30, 2014
Started 2009
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| Riverside Methodist Hospital | Columbus | Ohio | 43214 | — |
| Tulsa Cancer Institute | Tulsa | Oklahoma | 74146 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00814086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 30, 2014 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00814086 live on ClinicalTrials.gov.